company background image
IKT

Inhibikase Therapeutics NasdaqCM:IKT Stock Report

Last Price

US$0.93

Market Cap

US$23.3m

7D

14.2%

1Y

-51.6%

Updated

12 Aug, 2022

Data

Company Financials
IKT fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

IKT Stock Overview

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain.

Inhibikase Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Inhibikase Therapeutics
Historical stock prices
Current Share PriceUS$0.93
52 Week HighUS$2.54
52 Week LowUS$0.60
Beta0
1 Month Change8.87%
3 Month Change38.10%
1 Year Change-51.55%
3 Year Changen/a
5 Year Changen/a
Change since IPO-90.65%

Recent News & Updates

Aug 12

Inhibikase Therapeutics GAAP EPS of -$0.18, revenue of $6.55M

Inhibikase Therapeutics press release (NASDAQ:IKT): Q2 GAAP EPS of -$0.18. Revenue of $6.55K (-99.5% Y/Y). Cash and cash equivalents were $32.2 million as of June 30, 2022. The Company expects that existing cash and cash equivalents will be sufficient to fund its normal operations and capital expenditure requirements through December 31, 2023. Shares -2.73%.

Aug 09
Will Inhibikase Therapeutics (NASDAQ:IKT) Spend Its Cash Wisely?

Will Inhibikase Therapeutics (NASDAQ:IKT) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Shareholder Returns

IKTUS BiotechsUS Market
7D14.2%1.2%1.3%
1Y-51.6%-23.0%-11.7%

Return vs Industry: IKT underperformed the US Biotechs industry which returned -23% over the past year.

Return vs Market: IKT underperformed the US Market which returned -11.7% over the past year.

Price Volatility

Is IKT's price volatile compared to industry and market?
IKT volatility
IKT Average Weekly Movement12.7%
Biotechs Industry Average Movement12.5%
Market Average Movement7.8%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: IKT is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: IKT's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
20087Milton Wernerhttps://www.inhibikase.com

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases.

Inhibikase Therapeutics, Inc. Fundamentals Summary

How do Inhibikase Therapeutics's earnings and revenue compare to its market cap?
IKT fundamental statistics
Market CapUS$23.34m
Earnings (TTM)-US$16.79m
Revenue (TTM)US$1.74m

13.4x

P/S Ratio

-1.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
IKT income statement (TTM)
RevenueUS$1.74m
Cost of RevenueUS$11.94m
Gross Profit-US$10.20m
Other ExpensesUS$6.58m
Earnings-US$16.79m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

Aug 12, 2022

Earnings per share (EPS)-0.67
Gross Margin-586.66%
Net Profit Margin-965.21%
Debt/Equity Ratio0.0%

How did IKT perform over the long term?

See historical performance and comparison